1BAX Stock Chart & Stats
€20.52
€0.92(4.83%)
At close: 4:00 PM EDT
€20.52
€0.92(4.83%)
Day’s Range― - ―
52-Week Range€8.00 - €29.00
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€11.72B
Enterprise Value€17.72K
Total Cash (Recent Filing)€2.15B
Total Debt (Recent Filing)€9.67B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Oct 29, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding516,996,000
10 Day Avg. Volume127
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.59Price Target Upside10.07% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)1.74
Revenue Forecast (FY)€10.01B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueBaxter’s revenue mix is anchored in repeat consumables (IV fluids, administration sets, dialysis supplies), creating predictable reorder cycles and stable installed‑base demand. That recurring economics supports multi‑quarter revenue visibility, aftermarket margin durability, and pricing leverage with hospital and dialysis customers.
Positive Cash Generation And FCFSustained positive operating cash flow and free cash flow provide internal funding for working capital, capex and debt reduction. Even with accounting losses, consistent cash generation underpins the company’s plan to prioritize deleveraging and preserves optionality for tuck‑ins or reinvestment once leverage improves.
Product Launches And Operational ImprovementNew device and workflow launches, plus AI integration and a broad GPS continuous‑improvement rollout, expand addressable markets and strengthen device‑to‑consumable attach rates. Combined with progress clearing backorders, these moves enhance competitive positioning and long‑term operational resilience.
Bears Say
Weak Profitability And Negative MarginsNegative operating and net margins erode returns and limit internal reinvestment capacity. Persistent unprofitability reduces ROE and heightens reliance on cash flow improvements to restore sustainable earnings; absent structural margin recovery, growth investments and shareholder returns will be constrained.
Elevated LeverageMeaningful debt levels make the company interest‑sensitive and restrict strategic flexibility. Management’s focus on reducing net leverage to ~3x implies capital allocation tradeoffs—debt paydown ahead of larger M&A or buybacks—limiting near‑term ability to accelerate growth or return capital.
Operational And Supply Risks (Novum, Injectables, Tariffs)Product holds, manufacturer disruptions and material tariff headwinds are structural operational risks that can depress volumes, force returns/exchanges, and raise per‑unit costs. These issues prolong margin recovery timelines and increase execution risk for management’s turnaround plans.
Baxter International News
1BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was €8.00 and its highest was €29.00 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is €11.72B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Jul 30, 2026. The company reported €0.485 earnings per share for the quarter, beating the consensus estimate of €0.318 by €0.167.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International does not currently pay dividends.
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.45.
How many shares outstanding does Baxter International have?
Baxter International has 516,996,000 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of €0.485 in its last earnings report, beating expectations of €0.318. Following the earnings report the stock price went up 10.397%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in IT:1BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€22.59 (10.07% Upside)
€22.59 (10.07% Upside)
Blogger Sentiment
Neutral
IT:1BAX Sentiment 57%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.47%
12-Months-Change
Fundamentals
Return on Equity
0.77%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
1BAX Company Deck
1BAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all IT:1BAX earnings summaries1BAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
1BAX Stock 12 Month Forecast
Average Price Target
€22.59
▲(10.07% Upside)